Live tape
Top 8, mentions 7d15,460NVDA4,390 mentions▲ +0.04GOOGL2,568 mentions▲ +0.04AMD1,926 mentions▲ +0.08SPY1,738 mentions▲ +0.06QQQ1,669 mentions▲ +0.05SPCX1,134 mentions▲ +0.06TSLA1,027 mentions▲ +0.05AAPL1,008 mentions▲ +0.05

Equity · Healthcare

PRAX

NASDAQ

Praxis Precision Medicines (PRAX)

285.90 USD −0.95% vs prior close Oct 30, 2026
Praxis Precision Medicines, Inc. price graph
51 sessions
400 200 14 Aug 30 Oct

The line runs 367.02 USD on 14 August through 285.90 USD on 30 October, on a scale from 200 to 400. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
8.0B USD
Revenue, year to Dec 2025
0 USD
EPS, diluted, year to Dec 2025
−13.48 USD
52-week range
164 USD – 386 USD
Avg volume
31.3K

as of Oct 30, 2026

Have Praxis Precision Medicines (PRAX) insiders bought or sold shares recently?

PRAX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 8 July 2026.

Form 4

Have Praxis Precision Medicines (PRAX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
24 Jun 2026DeSimone JillDirectorSell11,6003.6M USD
20 Nov 2025Mastrocola LaurenPrincipal Accounting OfficerSell13,6002.6M USD
20 Nov 2025Nemiroff AlexGeneral Counsel and SecretarySell25,1304.9M USD
16 Oct 2025Adage Capital Management, L.P.Sell313,91033.2M USD
Sold4 open-market sales364,240$44.27M
39 other filings: grants, exercises, tax withholding and transfers, not trades
Have Praxis Precision Medicines (PRAX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
08 Jul 2026Souza MarcioChief Executive OfficerGift23,121
24 Jun 2026DeSimone JillDirectorOption exercise11,600826K USD
10 Jun 2026Arbuckle Stuart ADirectorAward1,371
10 Jun 2026Chodakewitz JeffreyDirectorAward1,371
10 Jun 2026Cudkowicz Merit EsterDirectorAward1,371
10 Jun 2026DeSimone JillDirectorAward1,371
10 Jun 2026KINDLER JEFFREY BDirectorAward1,371
10 Jun 2026MITCHELL DEAN JDirectorAward1,371
10 Jun 2026Norden GregoryDirectorAward1,371
10 Jun 2026YOUNG WILLIAM DDirectorAward1,371
14 May 2026Kelly Timothy EdwinChief Financial OfficerAward12120K USD
14 May 2026Mastrocola LaurenPrincipal Accounting OfficerAward12721K USD

Showing the 12 most recent of 39 compensation filings in this window. The figures above count all of them.

Which funds hold Praxis Precision Medicines (PRAX)?

10 of the 45 institutional funds we track reported a Praxis Precision Medicines position for the quarter ended 30 Jun 2026 — a combined 671.6M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Praxis Precision Medicines (PRAX)?
FundPositionSharesValueShares q/q
Baker Bros. AdvisorsHeld (±25%)1,753,198587.0M USD
Marshall WaceAdded137,00845.9M USD+203.5%
AQR Capital ManagementHeld (±25%)58,44619.6M USD−0.4%
Man GroupAdded21,1647.1M USD+567.0%
Two Sigma InvestmentsHeld (±25%)18,7586.3M USD+6.6%
Citadel AdvisorsNew position7,3312.5M USD
D. E. Shaw & Co.New position5,1401.7M USD
Tudor Investment CorpNew position2,183731K USD
Balyasny Asset ManagementNew position1,880629K USD
Millennium ManagementTrimmed995333K USD−74.0%

Have members of Congress traded Praxis Precision Medicines (PRAX)?

The most recent congressional trade disclosed in Praxis Precision Medicines is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.

STOCK Act disclosures

Have members of Congress traded Praxis Precision Medicines (PRAX)?
TradedMemberTypeAmountFiled after
29 Sep 2026Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD13 days

What has been filed or recorded for Praxis Precision Medicines (PRAX)?

The filings we hold for Praxis Precision Medicines, newest first: 9 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Praxis Precision Medicines (PRAX)?
And
14 Oct 2026Fails to deliverShares failed to deliver26,972 shares6.6M USD notional · 0.097% of shares out
13 Oct 2026Fails to deliverShares failed to deliver323 shares81K USD notional · 0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver17 shares4K USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver2,334 shares649K USD notional · 0.008% of shares out
06 Oct 2026Fails to deliverShares failed to deliver596 shares169K USD notional · 0.002% of shares out
05 Oct 2026Fails to deliverShares failed to deliver325 shares96K USD notional · 0.001% of shares out
02 Oct 2026Fails to deliverShares failed to deliver65 shares19K USD notional · <0.001% of shares out
01 Oct 2026Fails to deliverShares failed to deliver323 shares94K USD notional · 0.001% of shares out
30 Sep 2026Fails to deliverShares failed to deliver73 shares21K USD notional · <0.001% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −2.87 USD
30 Jun 2026FinancialsTotal assets1.4B USDat period end
30 Jun 2026FinancialsTotal equity1.3B USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −3.20 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −13.48 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−303.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−13.48 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −3.36 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −3.31 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −3.29 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −10.21 USDRevenue $9M
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −2.75 USDRevenue $0M

Praxis Precision Medicines (PRAX): frequently asked questions

From live data
285.90

What did Praxis Precision Medicines shares close at?

Praxis Precision Medicines closed at 285.90 USD on 30 Oct 2026, down 0.95% on the close before. That is the end-of-day price from Finazon, not a live quote.

8.0B

What is Praxis Precision Medicines’ market cap?

Praxis Precision Medicines is worth 8.0B USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.

0

What is Praxis Precision Medicines’ revenue?

Praxis Precision Medicines reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Praxis Precision Medicines insiders bought or sold shares recently?

No Praxis Precision Medicines insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 8 Jul 2026 (SEC Form 4). See Insiders

10 of 45

Which funds own Praxis Precision Medicines?

10 of the 45 funds we track reported a Praxis Precision Medicines position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Marshall Wace and AQR Capital Management. See Funds

1 trade

Have members of Congress traded Praxis Precision Medicines?

Yes. 1 trade in Praxis Precision Medicines appears in the congressional disclosures we hold: a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 29 Sep 2026, filed 12 Oct 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

−2.87

When did Praxis Precision Medicines last report earnings?

Praxis Precision Medicines last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −2.87 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings